Analysts Expect Akebia Therapeutics Inc (AKBA) to Post -$0.40 EPS

Analysts expect that Akebia Therapeutics Inc (NASDAQ:AKBA) will report earnings of ($0.40) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Akebia Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.42). Akebia Therapeutics posted earnings of ($0.48) per share in the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The firm is expected to announce its next earnings report on Wednesday, May 8th.

On average, analysts expect that Akebia Therapeutics will report full year earnings of ($1.31) per share for the current financial year, with EPS estimates ranging from ($1.82) to ($0.84). For the next year, analysts expect that the company will post earnings of ($0.60) per share, with EPS estimates ranging from ($1.70) to $0.35. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Akebia Therapeutics.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Tuesday, March 26th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.64). Akebia Therapeutics had a negative return on equity of 49.78% and a negative net margin of 69.12%. The company had revenue of $59.85 million for the quarter, compared to analysts’ expectations of $78.87 million.

A number of research firms have recently weighed in on AKBA. BidaskClub lowered Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 18th. Zacks Investment Research lowered Akebia Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. Finally, Citigroup began coverage on Akebia Therapeutics in a research report on Wednesday, March 20th. They set a “neutral” rating and a $9.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $14.28.

Shares of Akebia Therapeutics stock traded down $0.09 during trading hours on Friday, reaching $6.37. 580,271 shares of the company were exchanged, compared to its average volume of 1,307,968. Akebia Therapeutics has a 1 year low of $5.20 and a 1 year high of $11.60. The firm has a market capitalization of $746.07 million, a P/E ratio of -2.61 and a beta of 1.48.

A number of large investors have recently bought and sold shares of AKBA. Baupost Group LLC MA purchased a new position in Akebia Therapeutics in the fourth quarter valued at $135,327,000. BlackRock Inc. increased its holdings in Akebia Therapeutics by 57.5% in the fourth quarter. BlackRock Inc. now owns 8,296,503 shares of the biopharmaceutical company’s stock valued at $45,881,000 after buying an additional 3,027,657 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Akebia Therapeutics by 787,904.7% in the third quarter. Clearbridge Investments LLC now owns 1,016,526 shares of the biopharmaceutical company’s stock valued at $8,976,000 after buying an additional 1,016,397 shares during the last quarter. Norges Bank purchased a new position in Akebia Therapeutics in the fourth quarter valued at $3,497,000. Finally, Morgan Stanley increased its holdings in Akebia Therapeutics by 35.7% in the third quarter. Morgan Stanley now owns 1,887,436 shares of the biopharmaceutical company’s stock valued at $16,666,000 after buying an additional 496,069 shares during the last quarter. 68.49% of the stock is currently owned by hedge funds and other institutional investors.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.

See Also: What are economic reports?

Get a free copy of the Zacks research report on Akebia Therapeutics (AKBA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.